KR20230055253A - A traditional Chinese medicine composition and a preparation method thereof - Google Patents
A traditional Chinese medicine composition and a preparation method thereof Download PDFInfo
- Publication number
- KR20230055253A KR20230055253A KR1020210138761A KR20210138761A KR20230055253A KR 20230055253 A KR20230055253 A KR 20230055253A KR 1020210138761 A KR1020210138761 A KR 1020210138761A KR 20210138761 A KR20210138761 A KR 20210138761A KR 20230055253 A KR20230055253 A KR 20230055253A
- Authority
- KR
- South Korea
- Prior art keywords
- parts
- weight
- rhubarb
- heating
- extraction
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 239000003814 drug Substances 0.000 title abstract description 19
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 208000007514 Herpes zoster Diseases 0.000 claims abstract description 38
- 235000009411 Rheum rhabarbarum Nutrition 0.000 claims abstract description 23
- 241001071795 Gentiana Species 0.000 claims abstract description 22
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 18
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 18
- 241001571446 Scaphium scaphigerum Species 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 241000972673 Phellodendron amurense Species 0.000 claims abstract description 16
- 239000000843 powder Substances 0.000 claims description 40
- 238000000605 extraction Methods 0.000 claims description 38
- 239000000284 extract Substances 0.000 claims description 31
- 238000010438 heat treatment Methods 0.000 claims description 24
- 241000219061 Rheum Species 0.000 claims description 22
- 238000001914 filtration Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 5
- 239000010931 gold Substances 0.000 claims description 5
- 229910052737 gold Inorganic materials 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 9
- 231100000241 scar Toxicity 0.000 abstract description 5
- 208000032544 Cicatrix Diseases 0.000 abstract description 4
- 239000004480 active ingredient Substances 0.000 abstract description 4
- 208000004296 neuralgia Diseases 0.000 abstract description 4
- 230000037387 scars Effects 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract description 2
- 238000001035 drying Methods 0.000 abstract description 2
- 230000037257 muscle growth Effects 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 230000002195 synergetic effect Effects 0.000 abstract description 2
- 241000219063 Rheum rhabarbarum [NCBITaxon:3621] Species 0.000 abstract 1
- 238000001784 detoxification Methods 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 239000008399 tap water Substances 0.000 description 20
- 235000020679 tap water Nutrition 0.000 description 20
- 239000007788 liquid Substances 0.000 description 8
- 230000005484 gravity Effects 0.000 description 7
- 208000010201 Exanthema Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 3
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000021270 cold food Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 235000014102 seafood Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 235000021259 spicy food Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- MDNWOSOZYLHTCG-UHFFFAOYSA-N Dichlorophen Chemical compound OC1=CC=C(Cl)C=C1CC1=CC(Cl)=CC=C1O MDNWOSOZYLHTCG-UHFFFAOYSA-N 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- OIRDTQYFTABQOQ-UHTZMRCNSA-N Vidarabine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O OIRDTQYFTABQOQ-UHTZMRCNSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- -1 pain relievers Substances 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000037921 secondary disease Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940126702 topical medication Drugs 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 229960003636 vidarabine Drugs 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/756—Phellodendron, e.g. corktree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 중국 전통 의약 및 이의 제조방법에 관한 것으로, 특히 대상포진 치료용 약학조성물 및 이의 제조방법에 관한 것이다.The present invention relates to traditional Chinese medicine and a method for preparing the same, and more particularly to a pharmaceutical composition for treating herpes zoster and a method for preparing the same.
대상포진은 수두-대상포진 바이러스 감염에 의해 발생하는 바이러스성 피부질환으로 말초신경을 따라 분포하는 군집포진과 신경통을 특징으로 하며 봄에 가장 많이 발생한다.Herpes zoster is a viral skin disease caused by infection with the varicella-zoster virus and is characterized by cluster herpes distributed along the peripheral nerves and neuralgia, and occurs most frequently in spring.
현대의학에서는 대상포진 바이러스가 호흡기계 감염으로 몸에 침입하여 척수신경이나 다른 신경의 신경세포에 숨어 있는 질병으로 보고 있다. 이 바이러스는 보통 병에 걸리지 않으나 노약자나 노약자의 면역체계가 저하되어 육체적 피로, 감기 등의 경우에 대상포진을 유발하기 쉽다.Modern medicine sees the herpes zoster virus as a disease that invades the body through respiratory infection and hides in the nerve cells of the spinal nerves or other nerves. This virus usually does not cause disease, but it is easy to cause shingles in the case of physical fatigue, cold, etc. because the immune system of the elderly or the elderly is reduced.
대상포진 치료에 사용되는 주요 경구용 서양 의약은 항바이러스제, 진통제, 면역조절제, 코르티코스테로이드 등이다. 항바이러스제에는 아시클로비르, 발라시클로비르, 비다라빈, 아시클로비르 및 인터페론이 있다. 항염증 진통제는 아스피린, 안티펜정, 비타민 B1, 비타민 B12 등과 같은 것이다. 국소 환부에 대한 국소 약물은: 2% 젤라틴 바이올렛 용액 또는 외부에서 사용하는 산기소르바 아연 산화유 화합물을 포함한다. 2차 감염이 있는 경우 외부에서 네오마이신 연고를 사용할 수 있다.The main oral Western medicines used to treat herpes zoster include antivirals, pain relievers, immunomodulators, and corticosteroids. Antiviral agents include acyclovir, valacyclovir, vidarabine, acyclovir, and interferon. Anti-inflammatory analgesics include aspirin, antiphen tablets, vitamin B1, vitamin B12, and the like. Topical medications for topical sores include: 2% gelatin violet solution or externally used acid sorba zinc oil compound. Neomycin ointment can be used externally if there is a secondary infection.
위에서 언급한 치료 방법과 약물은 통증을 완화하고 임상 헤르페스 증상을 제거할 수 있다. 그러나 서양의학 치료는 치료기간이 길고 간과 신장의 손상이 심하고 부작용이 크고 치료비용이 비싸며 신경통 후유증이 잘 발생하고 완치 후 재발이 쉬운 단점이 있다.The treatment methods and medications mentioned above can relieve pain and eliminate clinical herpes symptoms. However, Western medicine treatment has the disadvantage of long treatment period, severe liver and kidney damage, high side effects, high treatment cost, frequent sequelae of neuralgia, and easy recurrence after complete recovery.
본 발명은 상기와 같은 문제점을 감안한 대상포진 치료용 조성물 및 이의 제조방법을 제공하는 것을 일차 목적으로 한다. 이 조성물은 대상포진의 병인 및 발병에 초점을 두고 다양한 중국 전통 의약의 활성 성분의 상승효과를 활용한다. 본 발명의 조성물은 열과 독소를 제거하고 습기와 통증을 제거하며 혈액 정체를 제거하고 해독하고 제거하고 부패를 제거하고 근육 성장을 촉진하여 흉터, 신경통 및 기타 후유증을 남기지 않고 대상포진을 치료할 수 있다.A primary object of the present invention is to provide a composition for treating shingles and a method for preparing the same in consideration of the above problems. This composition utilizes the synergistic effects of the active ingredients of various traditional Chinese medicines with a focus on the etiology and pathogenesis of shingles. The composition of the present invention can remove heat and toxins, remove moisture and pain, remove blood stasis, detoxify, remove, remove decay, and promote muscle growth, so as to treat shingles without leaving scars, neuralgia and other sequelae.
본 발명의 목적을 달성하기 위하여, 본 발명의 일 측면은 하기의 원료를 주성분으로 하는 대상포진 치료용 조성물을 제공한다: 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草).In order to achieve the object of the present invention, one aspect of the present invention provides a composition for treating shingles, which has the following raw materials as main components: Scutellaria scaphigera, 黃連, gold (Scutellaria baicalensis Georgi, 黃芩), yellow white ( Phellodendron amurense (黃柏), rhubarb (Rhubarb, 大黃), gentian (Gentian, 龍膽草).
상기 원료의 중량비(weight ratio)는 황련(Sterculia scaphigera, 黃連) 3-20, 황금(Scutellaria baicalensis Georgi, 黃芩) 2-15, 황백(Phellodendron amurense, 黃柏) 3-15, 대황(Rhubarb, 大黃) 2-20, 용담초(Gentian, 龍膽草) 3-15이다.The weight ratio of the raw materials is 3-20 for Sterculia scaphigera, 2-15 for Scutellaria baicalensis Georgi, 3-15 for Phellodendron amurense, and 3-15 for rhubarb. 2-20, Gentian, 3-15.
본 발명의 다른 측면은 하기 단계를 포함하는 대상포진 치료용 조성물의 제조방법을 제공한다: 1) 다음과 같은 중량비로 원료를 준비한다. 황련(Sterculia scaphigera, 黃連) 3-20, 황금(Scutellaria baicalensis Georgi, 黃芩) 2-15, 황백(Phellodendron amurense, 黃柏) 3-15, 대황(Rhubarb, 大黃) 2-20, 용담초(Gentian, 龍膽草) 3-15; 2) 원료를 균일하게 혼합한 후, 혼합물을 가열하여 추출하고 추출물을 수집하는 단계; 3) 채취한 추출물을 농축하여 본 발명의 약제의 유효성분을 제조한다.Another aspect of the present invention provides a method for preparing a composition for treating shingles comprising the following steps: 1) Prepare raw materials in the following weight ratio. Sterculia scaphigera 3-20, Scutellaria baicalensis Georgi 2-15, Phellodendron amurense 3-15, Rhubarb 2-20, Gentian Dragons and Dragons) 3-15; 2) uniformly mixing the raw materials, extracting by heating the mixture, and collecting the extract; 3) Concentrate the collected extract to prepare the active ingredient of the drug of the present invention.
여기서, 원료의 양은 바람직하게는 황련(Sterculia scaphigera, 黃連) 5-10 중량부, 황금(Scutellaria baicalensis Georgi, 黃芩) 5-10 중량부, 황백(Phellodendron amurense, 黃柏) 5-10 중량부, 대황(Rhubarb, 大黃) 6-10 중량부, 용담초(Gentian, 龍膽草) 5-10 중량부 이다.Here, the amount of the raw material is preferably 5-10 parts by weight of Sterculia scaphigera, 5-10 parts by weight of gold (Scutellaria baicalensis Georgi, 黃芩), 5-10 parts by weight of Phellodendron amurense, rhubarb ( Rhubarb, 大黃) 6-10 parts by weight, gentian (Gentian, 龍膽草) 5-10 parts by weight.
상기 2) 단계는 원료를 분쇄한 후 혼합하는 단계이며, 가열추출은 다음과 같은 단계를 포함한다: A) 상기 혼합물을 물에 침지시키고, 이때 첨가된 물 대 혼합물의 중량비는 3-6:1이고, 침지 20-90분 후에 1차 가열 추출을 수행하며, 여기서 가열 온도는 100℃이고 가열 추출 시간은 1-5시간이다. B) 첫 번째 추출물을 여과하고 여액을 수집한다; C) 여과 잔류물(filter residue)에 물을 첨가하고 2차 가열 추출을 수행하는데, 여기서 첨가된 물 대 혼합물의 중량비는 1-5:1이고, 가열 온도는 100℃이고, 가열 추출은 시간은 1-3시간이다; D) 여과하고 2개의 여과된 여액을 합한다.Step 2) is a step of pulverizing and then mixing the raw materials, and the heating extraction includes the following steps: A) immersing the mixture in water, wherein the weight ratio of the added water to the mixture is 3-6:1 , and after 20-90 minutes of immersion, the first heat extraction is performed, wherein the heating temperature is 100 ° C. and the heat extraction time is 1-5 hours. B) filter the first extract and collect the filtrate; C) Water is added to the filter residue and secondary heating extraction is performed, wherein the weight ratio of the added water to the mixture is 1-5:1, the heating temperature is 100 ° C, and the heating extraction time is 1-3 hours; D) Filter and combine the two filtered filtrates.
특히, 원료는 입자 크기가 10-50 메쉬인 거친 분말로 분쇄된 다음 혼합된다; 상기 A) 단계의 침지시간은 30~60분인 것이 바람직하고, 첨가된 물 대 혼합물의 중량비는 4~6:1인 것이 바람직하며, 1차 가열추출 시간은 1~3시간인 것이 바람직하다; 상기 C) 단계에서 첨가된 물 대 혼합물의 중량비는 1-3:1이다.Specifically, the raw material is ground into a coarse powder with a particle size of 10-50 mesh and then mixed; The soaking time in the step A) is preferably 30 to 60 minutes, the weight ratio of the added water to the mixture is preferably 4 to 6:1, and the first heat extraction time is preferably 1 to 3 hours; The weight ratio of the water added in step C) to the mixture is 1-3:1.
여기서, 상기 3) 단계에서 추출물을 농축하는 경우, 온도는 80~100℃, 바람직하게는 100℃로 조절된다; 추출물은 비중 1.05-1.50의 농축 용액으로 농축되며, 바람직하게 비중은 1.10-1.35이다.Here, when concentrating the extract in step 3), the temperature is adjusted to 80 to 100 ° C, preferably 100 ° C; The extract is concentrated to a concentrated solution with a specific gravity of 1.05-1.50, preferably a specific gravity of 1.10-1.35.
본 발명의 의약의 유효성분은 붕해제, 윤활제, 결합제 등과 같은 상이한 제형을 제조하는데 필요한 다양한 통상적인 보조 물질과 함께 첨가될 수 있고, 통상적인 중국 전통 의약 제조 방법에 의해 임의의 통상적인 경구 제형으로, 예를 들어 알약, 분말, 정제, 과립, 캡슐, 경구 액체 등과 같은 제형으로 제조될 수 있다.The active ingredient of the medicine of the present invention can be added together with various conventional auxiliary substances necessary for preparing different dosage forms, such as disintegrants, lubricants, binders, etc., and can be formulated into any conventional oral dosage form by conventional Chinese traditional medicine preparation methods. , For example, it can be prepared into dosage forms such as pills, powders, tablets, granules, capsules, oral liquids, and the like.
본 발명에 의해 제조된 대상포진 치료용 조성물을 사용할 경우 하루에 각각 5~7g(생약)으로 1~2회 경구 복용한다. 임산부는 복용을 금합니다. 약을 복용하는 동안 매운 음식, 찬 음식, 해산물 음식, 기름진 음식, 흡연을 금한다. 5-10일 사용 후 통증이 사라지고 띠 모양의 물집이 사라지며 피부 발적과 부기가 회복된다. 치유 후 홍반이나 색소침착이 없고 흉터가 남지 않는다.When using the composition for the treatment of herpes zoster prepared by the present invention, 5 to 7 g (herbal medicine) is taken orally once or twice a day. Pregnant women are prohibited from taking it. Avoid spicy food, cold food, seafood food, oily food, and smoking while taking the medicine. After 5-10 days of use, pain disappears, band-shaped blisters disappear, and skin redness and swelling recover. After healing, there is no erythema or pigmentation, and no scars remain.
하기 시험예를 이용하여 본 발명의 대상포진 치료용 조성물의 임상적 치료 효과를 더욱 설명한다.The clinical therapeutic effect of the composition for treating herpes zoster of the present invention will be further explained using the following test examples.
시험예 1(Test Example 1). 본 발명의 대상포진 치료제 조성물이 대상포진 치료에 미치는 영향에 대한 임상적 관찰Test Example 1. Clinical observation of the effect of the composition for treating shingles of the present invention on the treatment of shingles
(1) 일반 정보:(1) General information:
치료 효과를 이해하기 위해, 본 발명의 대상포진 치료제 조성물(분말)에 대해 18-65세의 남성 환자 60명, 여성 환자 60명을 포함하여 총 120건의 사례를 관찰하였다. 사례를 무작위로 치료군과 대조군으로 나누었다. 이 중 치료군이 70건, 대조군이 50건이었다. 모두 대상포진으로 진단되었고 다른 합병증이나 이차 질환 없이 7일 이내에 발병하였다. 두 그룹 사이에 연령, 성별 및 질병 경과에 유의한 차이가 없었다.In order to understand the therapeutic effect, a total of 120 cases, including 60 male patients and 60 female patients aged 18 to 65, were observed for the composition (powder) for the treatment of herpes zoster of the present invention. Cases were randomly divided into treatment and control groups. Of these, 70 cases were in the treatment group and 50 cases were in the control group. All of them were diagnosed with herpes zoster and developed within 7 days without any other complications or secondary diseases. There were no significant differences in age, sex and disease course between the two groups.
(2) 대상포진의 진단기준:(2) Diagnostic criteria for herpes zoster:
1. 피부 병변은 대부분 녹두 크기의 수성 흉터로 덩어리로 모여 있으며 흉터 벽이 촘촘하고 기저부가 붉은색이며 종종 일측으로 분포하고 리본으로 배열되었다. 심한 경우 피부 병변이 출혈을 일으키거나 괴저 손상이 나타날 수 있다. 머리와 얼굴의 피부 병변은 더 심한 경향이 있다.1. The skin lesions are mostly watery scars the size of mung beans, clustered in clumps, with dense scar walls and a red base, often unilaterally distributed and arranged in ribbons. In severe cases, skin lesions may bleed or cause gangrene damage. Skin lesions of the head and face tend to be more severe.
2. 발진이 나타나기 전에 종종 피부에 따끔거림 또는 작열감이 있으며 경미한 신체 불편과 열이 동반될 수 있다.2. There is often a tingling or burning sensation on the skin before the appearance of a rash, which may be accompanied by mild body discomfort and fever.
3. 의식적인 통증이 뚜렷하고, 견딜 수 없을 정도로 심한 통증이 있거나 발진이 가라앉은 후에도 통증이 남는다.3. Conscious pain is evident, there is unbearably severe pain, or the pain remains even after the rash has subsided.
(3) 치료방법(3) Treatment method
치료군: 본 발명의 대상포진 치료용 조성물(분말)을 1일 2회, 각각 5-7g 경구투여(생약), 5-10일 동안 연속 복약, 복약 중에는 매운 음식, 찬 음식, 해산물 음식, 기름진 음식, 흡연을 금한다.Treatment group: Oral administration of the composition (powder) for treatment of herpes zoster of the present invention twice a day, 5-7 g each (herbal medicine), continuous administration for 5-10 days, spicy food, cold food, seafood food, greasy food during taking the medicine , prohibit smoking.
대조군: 아시클로비르(acyclovir) 정제를 매일 1일 3회, 0.2g/회 경구로 복용하였다.Control group: Acyclovir tablets were taken orally at 0.2 g/time, 3 times a day.
(4) 대상포진의 치료효과 평가기준:(4) Criteria for evaluating the treatment effect of herpes zoster:
1. 치료: 발진이 가라앉고 임상증상이 사라지고 통증 후유증이 없다.1. Treatment: The rash subsides, the clinical symptoms disappear, and there are no pain sequelae.
2. 개선: 발진이 약 30% 정도 가라앉고 통증이 현저히 감소되었다.2. Improvement: The rash subsided by about 30% and the pain was significantly reduced.
3. 치유되지 않음: 발진의 30% 미만이 가라앉았고 여전히 통증이 있다.3. Non-healing: Less than 30% of rashes have subsided and are still painful.
(5) 임상시험 결과(5) Clinical trial results
실험 결과를 표 1 및 2에 나타내었다.The experimental results are shown in Tables 1 and 2.
표 1. 대상포진 치료 결과표Table 1. Herpes zoster treatment result table
표 2: 대상포진 치료 결과표Table 2: Herpes zoster treatment results table
결과는 다음을 나타낸다:The result shows:
1. 본 발명의 대상포진 치료용 조성물의 치료 효과가 현저하고, 임상적 대상포진 발진이 소실되고; 치료율은 97.1%, 개선율은 2.9%, 총 유효율은 100%이다.1. The therapeutic effect of the composition for treating herpes zoster of the present invention is remarkable, and the clinical herpes zoster rash disappears; The cure rate was 97.1%, the improvement rate was 2.9%, and the total effective rate was 100%.
2. 본 발명의 대상포진 치료용 조성물은 효과가 빠르고 치료기간이 짧다. 치료 6-10일 후 환자의 치료 비율은 91.4%에 달하며 그 중: 1-2일의 치료율은 10%에 이른다; 3-5일의 치료율은 17.1%에 이른다; 6-10일 이내에 치료율은 64.3%에 이른다; 반면 대조군은 치료 기간이 길어 5일 이상의 치료가 필요했다.2. The composition for treating herpes zoster of the present invention has a fast effect and a short treatment period. After 6-10 days of treatment, the cure rate of patients reached 91.4%, of which: the cure rate of 1-2 days reached 10%; The cure rate of 3-5 days reached 17.1%; Within 6-10 days, the cure rate reached 64.3%; On the other hand, the control group had a long treatment period, requiring more than 5 days of treatment.
3. 본 발명의 약학적 조성물은 독성 부작용, 알레르기 반응 및 기타 부작용이 없는 것으로서, 본 발명의 대상포진 치료용 조성물이 인체에 대한 부작용이 없음을 나타낸다.3. The pharmaceutical composition of the present invention is free from toxic side effects, allergic reactions and other side effects, indicating that the composition for treating herpes zoster of the present invention has no side effects on the human body.
4. 본 발명의 제품을 피험자에게 사용한 후 추적 관찰하여 6-12개월 동안 대상포진의 재발이 없음을 관찰하였다.4. After using the product of the present invention on subjects, it was followed up and observed that there was no recurrence of herpes zoster for 6-12 months.
시험예 2. 본 발명의 대상포진 치료제 조성물의 임상약리 및 독성시험Test Example 2. Clinical pharmacology and toxicity test of the composition for the treatment of herpes zoster of the present invention
(1) 급성독성시험(1) Acute toxicity test
본 발명의 대상포진 치료용 분말 조성물을 곤명 마우스에 1000g(생약)/kg으로 투여하였다.The powder composition for treating herpes zoster of the present invention was administered to Kunming mice at 1000 g (herbal medicine)/kg.
독성 반응은 없었고 1주일 이내에 죽은 동물도 없었다.There were no toxic reactions and no animals died within 1 week.
(2) 장기독성시험(2) long-term toxicity test
본 발명의 대상포진 조성물 정제는 집쥐(rat)에 대한 장기독성시험을 실시하고, 고용량(성인용량의 100배)을 위관영양법으로 연속투여한다. 투여 기간은 길다(90일). 일반 성능, 체중, 음식 섭취량, 혈액학 및 혈청 생화학적 지표, 소변 루틴, 골수 분류, 장기 중량, 장기 계수가 검출 지표이며, 독성 상태를 종합적으로 평가하기 위해 다양한 동물 조직 및 장기의 병리학적 검사로 보완된다. 결과는 집쥐의 모든 지표가 정상임을 보여주었다. 조직병리학적 검사 결과 집쥐의 장기에는 이상이 없었다.The herpes zoster composition tablet of the present invention was subjected to a long-term toxicity test on rats, and a high dose (100 times the adult dose) was continuously administered by gavage. The duration of administration is long (90 days). General performance, body weight, food intake, hematology and serum biochemical parameters, urine routine, bone marrow classification, organ weight, and organ counts are detection indicators, complemented by pathological examination of various animal tissues and organs to comprehensively evaluate the toxic status. do. Results showed that all indicators of house mice were normal. As a result of histopathological examination, there were no abnormalities in the organs of the rats.
요약하면, 본 발명의 대상포진 치료제 조성물은 독성이 낮고 안전성 범위가 넓다.In summary, the composition for the treatment of herpes zoster of the present invention has low toxicity and a wide safety range.
실시예 1. 본 발명의 약제 캡슐의 제조Example 1. Preparation of pharmaceutical capsules of the present invention
1) 다음 비(ratio)에 따라 원료를 칭량한다(단위: g)1) Weigh raw materials according to the following ratio (Unit: g)
황련(Sterculia scaphigera, 黃連) 5, 황금(Scutellaria baicalensis Georgi, 黃芩) 15, 황백(Phellodendron amurense, 黃柏) 10, 대황(Rhubarb, 大黃) 10, 용담초(Gentian, 龍膽草) 5.Sterculia scaphigera (黃連) 5, Golden (Scutellaria baicalensis Georgi, 黃芩) 15, Yellow baek (Phellodendron amurense, 黃柏) 10, Rhubarb (大黃) 10, Gentian (龍膽草) 5.
이중 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草)는 각각 거친 분말로 분쇄되는데 여기서 거친 분말의 크기는 24~50mesh 이고 균일하게 혼합되어 나중 사용을 위해 거친 분말 혼합물로 제조한다. Of these, Sterculia scaphigera (黃連), Scutellaria baicalensis Georgi (黃芩), Phellodendron amurense (黃柏), Rhubarb (大黃), and Gentian (龍膽草) are each ground into coarse powder. Here, the size of the coarse powder is 24 to 50 mesh and is uniformly mixed to prepare a coarse powder mixture for later use.
2) 균일하게 혼합된 거친 분말 혼합물을 중국 전통 의약 다기능 추출 주전자에 넣고 수돗물을 넣어 30분간 침지하며, 첨가한 수돗물의 중량과 거친 분말 혼합물의 중량비는 6:1이 되도록 한다. 2) Put the uniformly mixed coarse powder mixture into a traditional Chinese medicine multi-functional extraction kettle, add tap water and soak for 30 minutes, and set the weight ratio of the added tap water to the coarse powder mixture to be 6:1.
3) 가열을 하기 위해 다기능 추출 주전자의 전원을 켜고 100℃로 가열하고 이 온도에서 유지하고 2시간 동안 들어올린 다음 여과하여 첫 번째 추출물을 얻는다.3) Turn on the power of the multifunctional extraction kettle for heating, heat to 100 ° C, hold at this temperature, lift for 2 hours, and filter to obtain the first extract.
4) 여과 잔류물에 수돗물을 첨가하며, 첨가된 수돗물과 거친 분말 혼합물의 중량비는 3:1, 열 추출을 진행하며, 여기서 가열 온도는 100℃, 추출 시간은 1 시간이며, 그리고 두 번째 추출 액체는 여과에 의해 얻어진다;4) Add tap water to the filtration residue, the weight ratio of the added tap water and the coarse powder mixture is 3:1, proceed with thermal extraction, wherein the heating temperature is 100 ° C, the extraction time is 1 hour, and the second extraction liquid is obtained by filtration;
5) 두 추출물을 합하고 농축하여 비중 1.30의 추출물을 형성한 다음 45-50℃에서 건조하여 건조 추출물을 얻는다.5) The two extracts are combined and concentrated to form an extract having a specific gravity of 1.30, and then dried at 45-50° C. to obtain a dry extract.
6) 건조 추출물을 100-150 mesh의 미세한 분말로 분쇄한 후 경질 젤라틴 캡슐에 충전하여 완제품을 얻는다.6) The dried extract is pulverized into a fine powder of 100-150 mesh and filled into a hard gelatin capsule to obtain a finished product.
실시예 2. 본 발명의 의약 정제의 제조Example 2. Preparation of pharmaceutical tablets of the present invention
1) 다음 비(ratio)에 따라 원료를 칭량한다(단위: g)1) Weigh raw materials according to the following ratio (Unit: g)
황련(Sterculia scaphigera, 黃連) 10, 황금(Scutellaria baicalensis Georgi, 黃芩) 2, 황백(Phellodendron amurense, 黃柏) 5, 대황(Rhubarb, 大黃) 20, 용담초(Gentian, 龍膽草) 10.Sterculia scaphigera (黃連) 10, Golden (Scutellaria baicalensis Georgi, 黃芩) 2, Yellow baek (Phellodendron amurense, 黃柏) 5, Rhubarb (大黃) 20, Gentian (龍膽草) 10.
이중 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草)는 각각 거친 분말로 분쇄되는데 여기서 거친 분말의 크기는 24~50mesh 이고 균일하게 혼합되어 나중 사용을 위해 거친 분말 혼합물로 제조한다. Of these, Sterculia scaphigera (黃連), Scutellaria baicalensis Georgi (黃芩), Phellodendron amurense (黃柏), Rhubarb (大黃), and Gentian (龍膽草) are each ground into coarse powder. Here, the size of the coarse powder is 24 to 50 mesh and is uniformly mixed to prepare a coarse powder mixture for later use.
2) 균일하게 혼합된 거친 분말 혼합물을 전통 중국 의약 다기능 추출주전자에 넣고 수돗물을 넣어 60분간 불린다. 이때, 첨가한 수돗물과 거친 분말 혼합물의 중량비는 4:1로 한다.2) Put the uniformly mixed coarse powder mixture into a traditional Chinese medicine multifunctional extraction kettle and soak it in tap water for 60 minutes. At this time, the weight ratio of the added tap water and the coarse powder mixture was 4:1.
3) 가열을 위해 다기능 추출 주전자의 전원을 켜고 100℃로 가열하고 이 온도에서 유지하고 1.5시간 동안 들어 올린 다음 여과하여 첫 번째 추출물을 얻는다.3) Turn on the power of the multifunctional extraction kettle for heating, heat to 100 ° C, hold at this temperature, lift for 1.5 hours, and filter to obtain the first extract.
4) 여과 잔류물에 수돗물을 첨가하며, 첨가된 수돗물과 거친 분말 혼합물의 중량비는 3:1이고, 열 추출을 진행하며, 여기서 가열 온도는 100℃, 추출 시간은 1.5 시간이며, 두 번째 추출 액체는 여과에 의해 얻어진다.4) Add tap water to the filtration residue, the weight ratio of the added tap water and the coarse powder mixture is 3:1, proceed with thermal extraction, wherein the heating temperature is 100 ° C, the extraction time is 1.5 hours, and the second extraction liquid is obtained by filtration.
5) 두 추출물을 합하고 농축하여 비중 1.35의 추출물을 만든 다음 45-50℃에서 건조하여 건조 추출물을 얻는다.5) The two extracts are combined and concentrated to obtain an extract having a specific gravity of 1.35, and then dried at 45-50° C. to obtain a dry extract.
6) 건조추출물을 미세한 분말로 분쇄하고 부재료를 첨가하여 입자로 만든 후 건조시켜 정제로 만든다.6) Grind the dried extract into fine powder, add sub-materials to make particles, and then dry to make tablets.
실시예 3. 본 발명의 약제의 펠렛의 제조Example 3. Preparation of pellets of the medicament of the present invention
1) 다음 비(ratio)에 따라 원료를 칭량한다(단위: g)1) Weigh raw materials according to the following ratio (Unit: g)
황련(Sterculia scaphigera, 黃連) 3, 황금(Scutellaria baicalensis Georgi, 黃芩) 10, 황백(Phellodendron amurense, 黃柏) 15, 대황(Rhubarb, 大黃) 6, 용담초(Gentian, 龍膽草) 3.Sterculia scaphigera 3, Scutellaria baicalensis Georgi 10, Phellodendron amurense 15, Rhubarb 6, Gentian 3.
이중 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草)는 각각 거친 분말로 분쇄되는데 여기서 거친 분말의 크기는 24~50mesh 이고 균일하게 혼합되어 나중 사용을 위해 거친 분말 혼합물로 제조한다. Of these, Sterculia scaphigera (黃連), Scutellaria baicalensis Georgi (黃芩), Phellodendron amurense (黃柏), Rhubarb (大黃), and Gentian (龍膽草) are each ground into coarse powder. Here, the size of the coarse powder is 24 to 50 mesh and is uniformly mixed to prepare a coarse powder mixture for later use.
2) 균일하게 혼합된 거친 분말 혼합물을 전통 중국 의약 다기능 추출주전자에 넣고 수돗물을 넣어 20분간 불린다. 이때, 첨가한 수돗물과 거친 분말 혼합물의 중량비는 5:1로 한다.2) Put the uniformly mixed coarse powder mixture into a traditional Chinese medicine multifunctional extraction kettle and soak it in tap water for 20 minutes. At this time, the weight ratio of the added tap water and the coarse powder mixture was 5:1.
3) 가열을 위해 다기능 추출 주전자의 전원을 켜고 100℃로 가열하고 이 온도에서 유지하고 3시간 동안 들어 올린 다음 여과하여 첫 번째 추출물을 얻는다.3) Turn on the power of the multifunctional extraction kettle for heating, heat to 100 ° C, hold at this temperature, lift for 3 hours, and filter to obtain the first extract.
4) 여과 잔류물에 수돗물을 첨가하며, 첨가된 수돗물과 거친 분말 혼합물의 중량비는 1:1이고, 열 추출을 진행하며, 여기서 가열 온도는 100℃, 추출 시간은 1 시간이며, 두 번째 추출 액체는 여과에 의해 얻어진다.4) Add tap water to the filtration residue, the weight ratio of the added tap water and the coarse powder mixture is 1:1, proceed with thermal extraction, wherein the heating temperature is 100 ° C, the extraction time is 1 hour, and the second extraction liquid is obtained by filtration.
5) 두 추출물을 합하고 농축하여 비중 1.25의 추출물을 만든 다음 45-50℃에서 건조하여 건조 추출물을 얻는다.5) The two extracts are combined and concentrated to obtain an extract having a specific gravity of 1.25, and then dried at 45-50° C. to obtain a dry extract.
6) 건조 추출물을 미세 분말로 분쇄한 후 정제꿀을 부원료로 하여 혼합한다. 균일하게 저어준 후, 환제용 환제기에 넣고, 제조된 환제를 건조상자에서 건조시켜 완제품으로 만든다.6) After pulverizing the dried extract into fine powder, mix it with purified honey as an auxiliary ingredient. After uniformly stirring, it is put into a pill maker for pills, and the prepared pills are dried in a drying box to make a finished product.
실시예 4. 본 발명의 약제 입자의 제조Example 4. Preparation of drug particles of the present invention
1) 다음 비(ratio)에 따라 원료를 칭량한다(단위: g)1) Weigh raw materials according to the following ratio (Unit: g)
황련(Sterculia scaphigera, 黃連) 20, 황금(Scutellaria baicalensis Georgi, 黃芩) 5, 황백(Phellodendron amurense, 黃柏) 3, 대황(Rhubarb, 大黃) 2, 용담초(Gentian, 龍膽草) 15.Sterculia scaphigera 20, Scutellaria baicalensis Georgi 5, Phellodendron amurense 3, Rhubarb 2, Gentian 15.
이중 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草)는 각각 거친 분말로 분쇄되는데 여기서 거친 분말의 크기는 24~50mesh 이고 균일하게 혼합되어 나중 사용을 위해 거친 분말 혼합물로 제조한다. Of these, Sterculia scaphigera (黃連), Scutellaria baicalensis Georgi (黃芩), Phellodendron amurense (黃柏), Rhubarb (大黃), and Gentian (龍膽草) are each ground into coarse powder. Here, the size of the coarse powder is 24 to 50 mesh and is uniformly mixed to prepare a coarse powder mixture for later use.
2) 균일하게 혼합된 거친 분말 혼합물을 전통 중국 의약 다기능 추출주전자에 넣고 수돗물을 넣어 90분간 불린다. 이때, 첨가한 수돗물과 거친 분말 혼합물의 중량비는 3:1로 한다.2) Put the uniformly mixed coarse powder mixture into a traditional Chinese medicine multifunctional extraction kettle and soak it in tap water for 90 minutes. At this time, the weight ratio of the added tap water and the coarse powder mixture was 3:1.
3) 가열을 위해 다기능 추출 주전자의 전원을 켜고 100℃로 가열하고 이 온도에서 유지하고 1시간 동안 들어 올린 다음 여과하여 첫 번째 추출물을 얻는다.3) Turn on the power of the multifunctional extraction kettle for heating, heat to 100 ° C, hold at this temperature, lift for 1 hour, and filter to obtain the first extract.
4) 여과 잔류물에 수돗물을 첨가하며, 첨가된 수돗물과 거친 분말 혼합물의 중량비는 3:1이고, 열 추출을 진행하며, 여기서 가열 온도는 100℃, 추출 시간은 2 시간이며, 두 번째 추출 액체는 여과에 의해 얻어진다.4) Add tap water to the filtration residue, the weight ratio of the added tap water and the coarse powder mixture is 3:1, conduct thermal extraction, wherein the heating temperature is 100 ° C, the extraction time is 2 hours, and the second extraction liquid is obtained by filtration.
5) 두 추출물을 합하고 농축하여 비중 1.30의 추출물을 만든 다음 45-50℃에서 건조하여 건조 추출물을 얻는다.5) The two extracts are combined and concentrated to obtain an extract having a specific gravity of 1.30, and then dried at 45-50° C. to obtain a dry extract.
6) 건조 추출물을 미세 분말로 분쇄하고 결합제로 에탄올을 가하고 부원료 전분을 가하여 과립을 만든다.6) Grind the dried extract into fine powder, add ethanol as a binder, and add starch as an auxiliary material to make granules.
실시예 5. 본 발명의 약제의 경구용 액체의 제조Example 5. Preparation of an oral liquid of the medicament of the present invention
1) 다음 비(ratio)에 따라 원료를 칭량한다(단위: g)1) Weigh raw materials according to the following ratio (Unit: g)
황련(Sterculia scaphigera, 黃連) 7.5, 황금(Scutellaria baicalensis Georgi, 黃芩) 7.5, 황백(Phellodendron amurense, 黃柏) 7.5, 대황(Rhubarb, 大黃) 8, 용담초(Gentian, 龍膽草) 7.5.Sterculia scaphigera 7.5, Scutellaria baicalensis Georgi 7.5, Phellodendron amurense 7.5, Rhubarb 8, Gentian 7.5.
이중 황련(Sterculia scaphigera, 黃連), 황금(Scutellaria baicalensis Georgi, 黃芩), 황백(Phellodendron amurense, 黃柏), 대황(Rhubarb, 大黃), 용담초(Gentian, 龍膽草)는 각각 거친 분말로 분쇄되는데 여기서 거친 분말의 크기는 24~50mesh 이고 균일하게 혼합되어 나중 사용을 위해 거친 분말 혼합물로 제조한다. Of these, Sterculia scaphigera (黃連), Scutellaria baicalensis Georgi (黃芩), Phellodendron amurense (黃柏), Rhubarb (大黃), and Gentian (龍膽草) are each ground into coarse powder. Here, the size of the coarse powder is 24 to 50 mesh and is uniformly mixed to prepare a coarse powder mixture for later use.
2) 균일하게 혼합된 거친 분말 혼합물을 전통 중국 의약 다기능 추출주전자에 넣고 수돗물을 넣어 45분간 불린다. 이때, 첨가한 수돗물과 거친 분말 혼합물의 중량비는 6:1로 한다.2) Put the uniformly mixed coarse powder mixture into a traditional Chinese medicine multifunctional extraction kettle and soak it in tap water for 45 minutes. At this time, the weight ratio of the added tap water and the coarse powder mixture was 6:1.
3) 가열을 위해 다기능 추출 주전자의 전원을 켜고 100℃로 가열하고 이 온도에서 유지하고 2시간 동안 들어 올린 다음 여과하여 첫 번째 추출물을 얻는다.3) Turn on the power of the multifunctional extraction kettle for heating, heat to 100 ° C, hold at this temperature, lift for 2 hours, and filter to obtain the first extract.
4) 여과 잔류물에 수돗물을 첨가하며, 첨가된 수돗물과 거친 분말 혼합물의 중량비는 2:1이고, 열 추출을 진행하며, 여기서 가열 온도는 100℃, 추출 시간은 3 시간이며, 두 번째 추출 액체는 여과에 의해 얻어진다.4) Add tap water to the filtration residue, the weight ratio of the added tap water and the coarse powder mixture is 2:1, conduct thermal extraction, wherein the heating temperature is 100 ° C, the extraction time is 3 hours, and the second extraction liquid is obtained by filtration.
5) 두 추출물을 합하고 농축하여 비중 1.10의 추출물을 얻는다.5) Combine the two extracts and concentrate to obtain an extract with a specific gravity of 1.10.
6) 농축된 액체를 플라스틱 복합필름에 포장하여 경구용 액제를 만든다.6) The concentrated liquid is packaged in a plastic composite film to make an oral liquid formulation.
Claims (5)
황련(Sterculia scaphigera, 黃連) 5-10 중량부, 황금(Scutellaria baicalensis Georgi, 黃芩) 5-10 중량부, 황백(Phellodendron amurense, 黃柏) 5-10 중량부, 대황(Rhubarb, 大黃) 6-10 중량부, 용담초(Gentian, 龍膽草) 5-10 중량부를 포함하는 대상포진 치료용 조성물.According to claim 1,
Sterculia scaphigera, 5-10 parts by weight, Gold (Scutellaria baicalensis Georgi, 黃芩) 5-10 parts, Yellow 5-10 parts by weight, Rhubarb (Rhubarb, 大黃) 6-10 A composition for treating herpes zoster containing 5 to 10 parts by weight of gentian, gentian herb.
1) 원료로서 황련(Sterculia scaphigera, 黃連) 3-20 중량부, 황금(Scutellaria baicalensis Georgi, 黃芩) 2-15 중량부, 황백(Phellodendron amurense, 黃柏) 3-15 중량부, 대황(Rhubarb, 大黃) 2-20 중량부, 용담초(Gentian, 龍膽草) 3-15 중량부를 준비하는 단계;
2) 상기 원료를 균일하게 혼합한 후, 물을 첨가하여 침지하고, 상기 혼합물을 가열하고 추출하여 추출물을 수집하는 단계;
3) 채취한 추출물을 농축하는 단계를 포함하는,
방법. A method for preparing a pharmaceutical composition for treating herpes zoster, the method comprising:
1) As raw materials, 3-20 parts by weight of Sterculia scaphigera, 2-15 parts by weight of gold (Scutellaria baicalensis Georgi, 黃芩), 3-15 parts by weight of Phellodendron amurense, 3-15 parts by weight of rhubarb (Rhubarb, ) 2-20 parts by weight, preparing 3-15 parts by weight of Gentian;
2) uniformly mixing the raw materials, adding water to immersion, heating and extracting the mixture to collect extracts;
3) comprising the step of concentrating the collected extract,
method.
상기 단계 2) 에서 상기 원료는 분쇄된 후 혼합되고, 상기 가열 및 추출은:
A) 상기 혼합물을 물에 침지시키고, 이때 첨가된 물과 혼합물의 중량비는 3-6:1이고, 침지 20-90분 후에 1차 가열 추출을 수행하되, 여기서 가열 온도는 100℃이고 가열추출 시간은 1-5시간인, 1차 가열 및 추출 단계;
B) 첫 번째 추출물을 여과하고 여액을 수집하는 단계;
C) 여과 잔류물(filter residue)에 물을 첨가하고 2차 가열 및 추출을 수행하되, 여기서 첨가된 물과 혼합물의 중량비는 1-5:1이고, 가열 온도는 100℃이고, 가열 추출은 시간은 1-3시간인, 2차 가열 및 추출 단계;
D) 여과하고 2개의 여과된 여액을 합하는 단계;
를 포함하는,
방법.According to claim 3,
In step 2), the raw materials are pulverized and then mixed, and the heating and extraction are:
A) The mixture is immersed in water, wherein the weight ratio of the added water and the mixture is 3-6:1, and the first heat extraction is performed after 20-90 minutes of immersion, wherein the heating temperature is 100 ° C and the heat extraction time is 1-5 hours, the first heating and extraction step;
B) filtering the first extract and collecting the filtrate;
C) Water is added to the filter residue, and secondary heating and extraction are performed, wherein the weight ratio of the added water and the mixture is 1-5:1, the heating temperature is 100 ° C, and the heating extraction is performed for an hour. a second heating and extraction step, which is 1-3 hours;
D) filtering and combining the two filtered filtrate;
including,
method.
상기 원료는 10-50 메쉬 입자 크기를 갖는 거친 분말로 분쇄된 후 혼합되는,
방법.
According to claim 4,
The raw material is ground into a coarse powder having a particle size of 10-50 mesh and then mixed.
method.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210138761A KR20230055253A (en) | 2021-10-18 | 2021-10-18 | A traditional Chinese medicine composition and a preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210138761A KR20230055253A (en) | 2021-10-18 | 2021-10-18 | A traditional Chinese medicine composition and a preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20230055253A true KR20230055253A (en) | 2023-04-25 |
Family
ID=86101607
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210138761A KR20230055253A (en) | 2021-10-18 | 2021-10-18 | A traditional Chinese medicine composition and a preparation method thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20230055253A (en) |
-
2021
- 2021-10-18 KR KR1020210138761A patent/KR20230055253A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60117711T2 (en) | ANTINEOPLASTIC MEDICAMENT | |
DE3328262C2 (en) | ||
CN1286513C (en) | Chinese medicine composition for treating dermatosis and its preparing method | |
KR100601390B1 (en) | Anti-Obesity ingredients from medicinal plants and their composition | |
CN115414458B (en) | A Chinese medicinal composition for treating hepatitis B, and its preparation method | |
CN108721431B (en) | Traditional Chinese medicine composition for removing heavy metals and application thereof | |
CN103610795B (en) | A kind of preparation method of eucommia bark depressor oral formulations | |
KR20230055253A (en) | A traditional Chinese medicine composition and a preparation method thereof | |
CN112274619B (en) | Composition for relieving dysmenorrhea and application of composition in preparation of medicines, health-care products or foods | |
KR100912412B1 (en) | Pharmaceutics of traditional chinese medicine of treating AIDS and preparation method thereof | |
CN114632128A (en) | Collateral-dredging and turbid-removing formula and using method thereof | |
CN110721256B (en) | Traditional Chinese medicine composition for preventing and treating teniasis of laying hens and preparation method thereof | |
CN103585580B (en) | A kind of Chinese medicine preparation for recurrent oral ulceration | |
KR20230046094A (en) | A traditional Chinese medicine composition and a preparation method thereof | |
KR20230058899A (en) | A traditional Chinese medicine composition and a preparation method thereof | |
CN103933154B (en) | A kind of Chinese medicine composition treating goat and preparation method thereof | |
KR20230054100A (en) | A traditional Chinese medicine composition and a preparation method thereof | |
CN106943505B (en) | Traditional Chinese medicine composition for resisting prenatal stress syndrome for dogs and preparation method thereof | |
CN104491101A (en) | Preparing method of traditional Chinese medicine preparation for treatment of chronic renal failure | |
CN115025180B (en) | Blood-nourishing hair-growing pharmaceutical composition | |
CN111067947B (en) | Traditional Chinese medicine for removing dampness and relieving pain and preparation method thereof | |
CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
DE102021124936A1 (en) | Composition according to the type of traditional Chinese medicine and process for its preparation | |
CN115607644B (en) | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof | |
DE102021124583A1 (en) | Traditional Chinese drug composition and manufacturing process of the same |